Annual SG&A
$213.89 M
+$54.52 M+34.21%
31 December 2023
Summary:
BioCryst Pharmaceuticals annual selling, general & administrative expenses is currently $213.89 million, with the most recent change of +$54.52 million (+34.21%) on 31 December 2023. During the last 3 years, it has risen by +$145.97 million (+214.88%). BCRX annual SG&A is now at all-time high.BCRX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$65.08 M
+$3.87 M+6.32%
30 September 2024
Summary:
BioCryst Pharmaceuticals quarterly selling, general & administrative expenses is currently $65.08 million, with the most recent change of +$3.87 million (+6.32%) on 30 September 2024. Over the past year, it has increased by +$14.44 million (+28.50%). BCRX quarterly SG&A is now at all-time high.BCRX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$6.87 B
-$123.82 M-1.84%
30 September 2024
Summary:
BioCryst Pharmaceuticals TTM selling, general & administrative expenses is currently -$6.87 billion, with the most recent change of -$123.82 million (-1.84%) on 30 September 2024. Over the past year, it has dropped by -$7.07 billion (-3540.84%). BCRX TTM SG&A is now -42571.76% below its all-time high of $250.04 million, reached on 30 September 2024.BCRX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +34.2% | +28.5% | -3540.8% |
| 3 y3 years | +214.9% | +86.0% | -6679.5% |
| 5 y5 years | +624.7% | +454.6% | -10000.0% |
BCRX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +214.9% | at high | +89.8% | -55.0% | at low |
| 5 y | 5 years | at high | +624.7% | at high | +520.5% | -119.3% | at low |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | <-9999.0% | at low |
BioCryst Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $65.08 M(+6.3%) | $250.04 M(+6.1%) |
| June 2024 | - | $61.21 M(+3.1%) | $235.61 M(+4.5%) |
| Mar 2024 | - | $59.36 M(-7.8%) | $225.39 M(+5.4%) |
| Dec 2023 | $213.89 M(+34.2%) | $64.38 M(+27.1%) | $213.89 M(+7.1%) |
| Sept 2023 | - | $50.65 M(-0.7%) | $199.66 M(+7.4%) |
| June 2023 | - | $51.00 M(+6.5%) | $185.94 M(+7.5%) |
| Mar 2023 | - | $47.87 M(-4.6%) | $172.96 M(+8.5%) |
| Dec 2022 | $159.37 M(+34.1%) | $50.15 M(+35.8%) | $159.37 M(+10.2%) |
| Sept 2022 | - | $36.92 M(-2.9%) | $144.60 M(+1.4%) |
| June 2022 | - | $38.02 M(+10.9%) | $142.68 M(+8.9%) |
| Mar 2022 | - | $34.28 M(-3.1%) | $130.99 M(+10.2%) |
| Dec 2021 | $118.82 M(+74.9%) | $35.39 M(+1.1%) | $118.82 M(+13.8%) |
| Sept 2021 | - | $34.99 M(+32.9%) | $104.42 M(+20.5%) |
| June 2021 | - | $26.32 M(+19.0%) | $86.62 M(+16.8%) |
| Mar 2021 | - | $22.11 M(+5.4%) | $74.18 M(+9.2%) |
| Dec 2020 | $67.93 M(+83.0%) | $20.99 M(+22.0%) | $67.93 M(+18.3%) |
| Sept 2020 | - | $17.20 M(+23.9%) | $57.43 M(+10.5%) |
| June 2020 | - | $13.88 M(-12.5%) | $51.97 M(+11.2%) |
| Mar 2020 | - | $15.87 M(+51.3%) | $46.75 M(+25.9%) |
| Dec 2019 | $37.12 M(+25.8%) | $10.49 M(-10.6%) | $37.12 M(+19.3%) |
| Sept 2019 | - | $11.73 M(+35.5%) | $31.12 M(+14.0%) |
| June 2019 | - | $8.66 M(+38.8%) | $27.31 M(-3.0%) |
| Mar 2019 | - | $6.24 M(+38.9%) | $28.14 M(-4.6%) |
| Dec 2018 | $29.51 M(+111.8%) | $4.49 M(-43.3%) | $29.51 M(-0.7%) |
| Sept 2018 | - | $7.92 M(-16.5%) | $29.72 M(+18.2%) |
| June 2018 | - | $9.49 M(+24.7%) | $25.14 M(+36.0%) |
| Mar 2018 | - | $7.61 M(+62.0%) | $18.48 M(+32.7%) |
| Dec 2017 | $13.93 M(+23.8%) | $4.70 M(+40.5%) | $13.93 M(+18.1%) |
| Sept 2017 | - | $3.34 M(+18.0%) | $11.80 M(+5.2%) |
| June 2017 | - | $2.83 M(-7.3%) | $11.21 M(+1.0%) |
| Mar 2017 | - | $3.06 M(+19.4%) | $11.10 M(-1.4%) |
| Dec 2016 | $11.25 M(-13.8%) | $2.56 M(-7.1%) | $11.25 M(-1.4%) |
| Sept 2016 | - | $2.76 M(+1.2%) | $11.41 M(+0.2%) |
| June 2016 | - | $2.72 M(-15.2%) | $11.39 M(-6.6%) |
| Mar 2016 | - | $3.21 M(+18.0%) | $12.20 M(-6.5%) |
| Dec 2015 | $13.05 M(+74.9%) | $2.72 M(-0.4%) | $13.05 M(+5.4%) |
| Sept 2015 | - | $2.73 M(-22.7%) | $12.37 M(+8.0%) |
| June 2015 | - | $3.53 M(-13.0%) | $11.46 M(+15.3%) |
| Mar 2015 | - | $4.06 M(+98.3%) | $9.93 M(+33.1%) |
| Dec 2014 | $7.46 M(+24.2%) | $2.05 M(+13.0%) | $7.46 M(+9.2%) |
| Sept 2014 | - | $1.81 M(-10.0%) | $6.83 M(+3.5%) |
| June 2014 | - | $2.01 M(+26.8%) | $6.60 M(+9.7%) |
| Mar 2014 | - | $1.59 M(+12.0%) | $6.02 M(+0.2%) |
| Dec 2013 | $6.01 M(-34.2%) | $1.42 M(-10.2%) | $6.01 M(-31.9%) |
| Sept 2013 | - | $1.58 M(+10.3%) | $8.82 M(-0.1%) |
| June 2013 | - | $1.43 M(-9.3%) | $8.83 M(-2.0%) |
| Mar 2013 | - | $1.58 M(-62.7%) | $9.01 M(-1.3%) |
| Dec 2012 | $9.13 M(-23.8%) | $4.23 M(+166.1%) | $9.13 M(+31.3%) |
| Sept 2012 | - | $1.59 M(-1.1%) | $6.96 M(-16.4%) |
| June 2012 | - | $1.61 M(-5.2%) | $8.32 M(-18.8%) |
| Mar 2012 | - | $1.70 M(-17.6%) | $10.24 M(-15.2%) |
| Dec 2011 | $11.98 M(+2.2%) | $2.06 M(-30.3%) | $12.08 M(+10.4%) |
| Sept 2011 | - | $2.95 M(-16.5%) | $10.94 M(-7.1%) |
| June 2011 | - | $3.54 M(+0.1%) | $11.78 M(+2.9%) |
| Mar 2011 | - | $3.53 M(+284.2%) | $11.45 M(-2.3%) |
| Dec 2010 | $11.72 M(+2.1%) | $919.00 K(-75.8%) | $11.72 M(-18.9%) |
| Sept 2010 | - | $3.79 M(+18.2%) | $14.45 M(+5.3%) |
| June 2010 | - | $3.21 M(-15.5%) | $13.72 M(+7.0%) |
| Mar 2010 | - | $3.80 M(+4.1%) | $12.82 M(+11.7%) |
| Dec 2009 | $11.48 M | $3.65 M(+19.0%) | $11.48 M(+12.4%) |
| Sept 2009 | - | $3.06 M(+32.5%) | $10.21 M(+6.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | $2.31 M(-5.9%) | $9.62 M(-3.5%) |
| Mar 2009 | - | $2.46 M(+3.4%) | $9.97 M(-4.1%) |
| Dec 2008 | $10.40 M(+9.9%) | $2.38 M(-3.8%) | $10.40 M(-1.0%) |
| Sept 2008 | - | $2.47 M(-7.3%) | $10.51 M(-1.2%) |
| June 2008 | - | $2.67 M(-7.6%) | $10.63 M(+6.5%) |
| Mar 2008 | - | $2.89 M(+16.1%) | $9.98 M(+5.4%) |
| Dec 2007 | $9.47 M(+55.0%) | $2.49 M(-4.2%) | $9.47 M(+9.9%) |
| Sept 2007 | - | $2.60 M(+28.9%) | $8.61 M(+13.1%) |
| June 2007 | - | $2.01 M(-15.1%) | $7.61 M(+9.0%) |
| Mar 2007 | - | $2.37 M(+45.5%) | $6.99 M(+14.4%) |
| Dec 2006 | $6.11 M(+65.7%) | $1.63 M(+2.0%) | $6.11 M(+2.7%) |
| Sept 2006 | - | $1.60 M(+15.5%) | $5.95 M(+15.6%) |
| June 2006 | - | $1.38 M(-7.4%) | $5.14 M(+14.6%) |
| Mar 2006 | - | $1.50 M(+1.8%) | $4.49 M(+21.7%) |
| Dec 2005 | $3.69 M(+14.5%) | $1.47 M(+84.7%) | $3.69 M(+18.0%) |
| Sept 2005 | - | $795.00 K(+9.4%) | $3.12 M(+2.2%) |
| June 2005 | - | $727.00 K(+4.5%) | $3.06 M(-6.1%) |
| Mar 2005 | - | $696.00 K(-23.2%) | $3.26 M(+1.1%) |
| Dec 2004 | $3.22 M(+14.6%) | $905.70 K(+24.4%) | $3.22 M(-6.4%) |
| Sept 2004 | - | $728.00 K(-21.4%) | $3.44 M(+6.2%) |
| June 2004 | - | $926.00 K(+40.3%) | $3.24 M(+13.0%) |
| Mar 2004 | - | $660.00 K(-41.3%) | $2.86 M(+1.9%) |
| Dec 2003 | $2.81 M(-1.5%) | $1.12 M(+113.8%) | $2.81 M(+25.1%) |
| Sept 2003 | - | $526.00 K(-4.9%) | $2.25 M(-5.4%) |
| June 2003 | - | $553.00 K(-8.9%) | $2.37 M(-11.8%) |
| Mar 2003 | - | $607.00 K(+8.4%) | $2.69 M(-5.6%) |
| Dec 2002 | $2.86 M(-6.4%) | $559.80 K(-14.5%) | $2.85 M(-13.6%) |
| Sept 2002 | - | $655.00 K(-24.8%) | $3.30 M(-1.0%) |
| June 2002 | - | $871.00 K(+13.4%) | $3.34 M(+0.2%) |
| Mar 2002 | - | $768.00 K(-23.7%) | $3.33 M(+0.9%) |
| Dec 2001 | $3.05 M(-14.2%) | $1.01 M(+46.2%) | $3.30 M(+1.9%) |
| Sept 2001 | - | $689.00 K(-20.3%) | $3.24 M(-0.6%) |
| June 2001 | - | $865.00 K(+17.1%) | $3.26 M(-1.6%) |
| Mar 2001 | - | $739.00 K(-21.7%) | $3.31 M(-8.3%) |
| Dec 2000 | $3.56 M(+22.7%) | $944.30 K(+33.2%) | $3.61 M(+10.5%) |
| Sept 2000 | - | $709.00 K(-22.7%) | $3.27 M(+0.3%) |
| June 2000 | - | $917.00 K(-11.8%) | $3.26 M(+0.5%) |
| Mar 2000 | - | $1.04 M(+73.3%) | $3.24 M(+8.0%) |
| Dec 1999 | $2.90 M(-6.5%) | $600.00 K(-14.3%) | $3.00 M(0.0%) |
| Sept 1999 | - | $700.00 K(-22.2%) | $3.00 M(-14.3%) |
| June 1999 | - | $900.00 K(+12.5%) | $3.50 M(+6.1%) |
| Mar 1999 | - | $800.00 K(+33.3%) | $3.30 M(+6.5%) |
| Dec 1998 | $3.10 M(+14.8%) | $600.00 K(-50.0%) | $3.10 M(0.0%) |
| Sept 1998 | - | $1.20 M(+71.4%) | $3.10 M(+29.2%) |
| June 1998 | - | $700.00 K(+16.7%) | $2.40 M(-11.1%) |
| Mar 1998 | - | $600.00 K(0.0%) | $2.70 M(-3.6%) |
| Dec 1997 | $2.70 M(0.0%) | $600.00 K(+20.0%) | $2.80 M(0.0%) |
| Sept 1997 | - | $500.00 K(-50.0%) | $2.80 M(0.0%) |
| June 1997 | - | $1.00 M(+42.9%) | $2.80 M(-3.4%) |
| Mar 1997 | - | $700.00 K(+16.7%) | $2.90 M(+7.4%) |
| Dec 1996 | $2.70 M(+22.7%) | $600.00 K(+20.0%) | $2.70 M(-3.6%) |
| Sept 1996 | - | $500.00 K(-54.5%) | $2.80 M(0.0%) |
| June 1996 | - | $1.10 M(+120.0%) | $2.80 M(+27.3%) |
| Mar 1996 | - | $500.00 K(-28.6%) | $2.20 M(-4.3%) |
| Dec 1995 | $2.20 M(+15.8%) | $700.00 K(+40.0%) | $2.30 M(+15.0%) |
| Sept 1995 | - | $500.00 K(0.0%) | $2.00 M(+5.3%) |
| June 1995 | - | $500.00 K(-16.7%) | $1.90 M(-5.0%) |
| Mar 1995 | - | $600.00 K(+50.0%) | $2.00 M(+5.3%) |
| Dec 1994 | $1.90 M | $400.00 K(0.0%) | $1.90 M(+26.7%) |
| Sept 1994 | - | $400.00 K(-33.3%) | $1.50 M(+36.4%) |
| June 1994 | - | $600.00 K(+20.0%) | $1.10 M(+120.0%) |
| Mar 1994 | - | $500.00 K | $500.00 K |
FAQ
- What is BioCryst Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual SG&A year-on-year change?
- What is BioCryst Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly SG&A year-on-year change?
- What is BioCryst Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM SG&A year-on-year change?
What is BioCryst Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of BCRX is $213.89 M
What is the all time high annual SG&A for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual selling, general & administrative expenses is $213.89 M
What is BioCryst Pharmaceuticals annual SG&A year-on-year change?
Over the past year, BCRX annual selling, general & administrative expenses has changed by +$54.52 M (+34.21%)
What is BioCryst Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of BCRX is $65.08 M
What is the all time high quarterly SG&A for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $65.08 M
What is BioCryst Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, BCRX quarterly selling, general & administrative expenses has changed by +$14.44 M (+28.50%)
What is BioCryst Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of BCRX is -$6.87 B
What is the all time high TTM SG&A for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM selling, general & administrative expenses is $250.04 M
What is BioCryst Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, BCRX TTM selling, general & administrative expenses has changed by -$7.07 B (-3540.84%)